Assessing potential harms from screening overdiagnosis and false positives with multicancer early detection tests

A microsimulation study of multicancer early detection screening in Canada suggests that while overdiagnosis of indolent tumors is likely to be modest overall, the risk increases significantly with age and false positive results could substantially increase the diagnostic workload for healthcare systems.

The Gist

Imagine you have a brand-new, super-smart metal detector designed to find hidden treasure (cancer) in a massive field (your body). This new detector, called a Multicancer Early Detection (MCED) test, is exciting because it can sniff out many different types of treasure at once, even before they cause any trouble.

But, like any powerful tool, it has a few quirks that could cause some headaches. This paper is like a "safety report" asking: If we use this metal detector on everyone between the ages of 50 and 75, how often will it cause more problems than it solves?

Here is the breakdown of what the researchers found, using some everyday analogies:

1. The "False Alarm" Problem (False Positives)

Imagine your metal detector beeps loudly. You dig, but there's no treasure—just a soda can or a piece of old wire. In medical terms, this is a False Positive. The test says, "You have cancer!" but you actually don't.

• The Finding: Because the test is looking for so many different things, it sometimes gets confused. The study found that for every 1 real cancer the test finds, it might also trigger 0.3 to 5.3 false alarms where there is no cancer at all.
• The Consequence: This means a lot of people might get scared and have to undergo extra, expensive, and invasive tests (like biopsies) just to prove they are healthy. It's like calling the fire department because your smoke detector went off, only to find out it was just burnt toast.

2. The "Harmless Pebble" Problem (Overdiagnosis)

Now, imagine the detector finds a small, smooth stone that looks like a gem but is actually just a rock that will never grow or hurt you. In the medical world, this is an indolent tumor. It's a slow-growing cell cluster that would have stayed harmless for the rest of your life, perhaps never even being noticed if you hadn't taken the test.

• The Finding: The study found that the test might "find" these harmless pebbles. About 2% to 6% of all the "cancers" the test finds each year might be these harmless pebbles.
• The Age Factor: This gets trickier as you get older. At age 50, only about 1% of findings might be harmless. But by age 75, that number jumps to over 10%.
• The Consequence: If we treat these harmless pebbles like dangerous gems, we might perform unnecessary surgeries or give people chemotherapy for a "disease" they didn't actually need to worry about.

3. The Big Picture: Is it Worth It?

The researchers ran a complex computer simulation (like a video game that predicts the future) to see what would happen if the whole country used this test.

• The Good News: The "harmless pebble" problem (overdiagnosis) isn't as huge as some people feared. It won't overwhelm the system with unnecessary treatments for harmless conditions.
• The Bad News: The "false alarm" problem is significant. Because the test is so sensitive, it will flag a lot of healthy people as sick.

The Bottom Line

Think of this new test as a very eager security guard. It's great at catching the bad guys (real cancers), but it's also a bit paranoid and stops a lot of innocent people (false positives) for extra checks.

The takeaway for the future:
While this test is a promising tool, hospitals and health systems need to be ready. They can't just run the test; they need to make sure they have enough doctors and equipment to handle the wave of "false alarms" without causing panic or wasting resources. The test is a powerful flashlight, but we need to be careful not to trip over the shadows it casts.

Technical Summary

Technical Summary: Assessing Potential Harms from Screening Overdiagnosis and False Positives with Multicancer Early Detection Tests

1. Problem Statement

The emergence of Multicancer Early Detection (MCED) tests offers the potential to screen for multiple cancer types simultaneously, potentially improving early detection rates. However, the widespread adoption of these tests in population-based screening programs raises significant concerns regarding two primary harms:

• False Positives: Results indicating cancer in individuals who do not have the disease, leading to unnecessary anxiety and invasive follow-up procedures.
• Overdiagnosis: The detection of indolent (slow-growing) tumors that would never have progressed to cause clinical symptoms or death during the patient's lifetime. Detecting these leads to overtreatment and associated morbidity without survival benefit.

The core problem addressed by this study is quantifying the magnitude of these harms to determine if the benefits of MCED screening outweigh the risks at a population level.

2. Methodology

The researchers employed a microsimulation model to project the population-level impacts of MCED screening in a Canadian context. Key methodological components include:

• Target Population: Individuals aged 50 to 75 years.
• Test Parameters:
  • Specificity: Assumed to be high, ranging from 97% to 99.1%.
  • Sensitivity: Modeled as increasing with cancer stage (higher sensitivity for advanced stages).
  • Preclinical Screen-Detectable Period (SSDP): A range of 2 to 5 years was assumed to model the window during which a tumor is detectable by the test before clinical symptoms appear.
• Overdiagnosis Mechanism: The model explicitly included a compartment for latent indolent cancers. These are tumors that, if left undetected, would not be diagnosed within the individual's lifetime but would be identified through screening, constituting an overdiagnosis.
• Metrics Calculated:
  • Yearly and cumulative lifetime probabilities of overdiagnosis.
  • Yearly and cumulative lifetime probabilities of false positive results.
  • Positive Predictive Value (PPV) and the ratio of false positives to true positives.

3. Key Contributions

• Quantification of Overdiagnosis Risk: The study provides specific estimates for the proportion of screen-detected cancers that are likely to be overdiagnoses, a metric often difficult to measure in early-stage trials.
• Age-Stratified Analysis: It highlights that the risk profile is not static; the study demonstrates a strong correlation between increasing age and the probability of overdiagnosis.
• False Positive Ratio: The research translates abstract specificity rates into clinically relevant metrics, specifically the number of false positives expected per true cancer case detected.
• Healthcare System Impact: It shifts the focus from individual patient risk to the systemic burden, specifically how false positives might strain diagnostic service caseloads.

4. Key Results

• Overdiagnosis Rates:
  • Overall: Estimated 2.1% to 6.0% of all yearly screen-detected cancers are predicted to be overdiagnoses across various scenarios.
  • Age Dependency: The rate of overdiagnosis increases significantly with age. It starts at approximately 1% at age 50 and rises to over 10% by age 75.
  • Site Variability: The proportion of overdiagnosis varies depending on the specific cancer site.
• False Positives and Predictive Value:
  • Positive Predictive Value (PPV): Ranged from 15.9% to 77.6%, indicating significant variability in the likelihood that a positive test result represents actual cancer.
  • False Positive Ratio: For every true cancer case detected, there could be 0.3 to 5.3 false positives (individuals with no underlying cancer).
• Cumulative Impact: While yearly rates are manageable, the cumulative lifetime probability of experiencing a false positive or overdiagnosis increases with repeated screening cycles.

5. Significance and Conclusion

The study concludes that while population-level MCED screening is unlikely to result in substantial levels of screen-related overdiagnosis (capping at ~6% of detected cases), the issue of false positives is a critical operational challenge.

• Clinical Implication: The finding that false positives can outnumber true positives (up to 5.3:1 in lower PPV scenarios) suggests that a significant portion of the population will undergo unnecessary diagnostic workups.
• Policy Recommendation: Healthcare systems must proactively plan for the increased caseload on diagnostic services (e.g., biopsies, imaging) driven by these false positives. Without adequate infrastructure to handle this influx, the harms of screening (anxiety, procedural complications, resource strain) could potentially outweigh the benefits of early cancer detection.

In summary, the paper argues that MCED tests are a viable screening tool regarding overdiagnosis but requires robust system-level planning to manage the high volume of false positive results.